ABOUT US
The Genesis Of An Idea.
The Analytic for Hemodynamic Instability (AHI) and ultimately Fifth Eye originated from the idea that clinicians needed a better early warning indicator of an oncoming patient crash using existing physiologic information. The goal was to provide doctors and nurses an intuitive heads-up so they could take action to save the patient’s life.
The Beginning.
In 2014, a team of physicians, nurses, data scientists and computer scientists began exploring a data set developed by the U.S. Army that simulated hypovolemia (hemorrhage) on healthy volunteers. Using sophisticated machine learning techniques, the team looked at a variety of patient data streams and ultimately settled on using a single real-time stream of rich, information-dense ECG data to develop a proof of concept analytic that outperformed traditional vital signs in predicting patient deterioration.
From Army To Academic Hospital.
To further develop this concept, the University of Michigan’s Weil Institute for Critical Care Research & Innovation (formerly MCIRCC) developed a data collection framework, software tools and infrastructure to collect and store a vast dataset of deidentified patient waveform and numeric data. For four years, the Weil Institute for Critical Care Research & Innovation team, that would eventually become the Fifth Eye team, collaborated with internal critical care experts to do a deep retrospective dive into cases to determine how early the AHI analytic could predict the collapse that led to a Rapid Response Team (RRT) call. Results from their work show AHI consistently and reliably predicts the impending hemodynamic instability minutes to hours and sometimes even days in advance.
The Fifth Eye team deliberately built our clinical analytic on a single real-time stream of very rich, very information-dense ECG data which is widely used on many different types of patients today. This means that many patients will have the streaming data needed to use AHI – and AHI does not require baseline data and generates a first prediction with just 120 heartbeats of data. We have used customer-driven product design from the earliest stages. The core technology was developed with frequent and in-depth interactions with doctors and nurses to shape the direction of the technology development.
From Academic Hospital To The World.
In 2018, Fifth Eye licensed the technology from the University of Michigan in order to transform it into an easy to use and powerful tool for clinicians around the world. The Fifth Eye team has completed product development, received U.S. FDA grant of De Novo classification, and is now working with early adopting partners who are interested in being at the forefront of healthcare improvements.
Our Team
JEN BAIRD
CEO, BOARD MEMBER
Successful venture-backed serial entrepreneur
JEFF BASCH
CFO
Broad cross-functional management expertise across multiple startups
MARK SALAMANGO
CTO, BOARD MEMBER
25+ years leading software product development teams
ASHWIN BELLE, PHD
CHIEF ANALYTICS OFFICER
Expert data scientist with specialization in signal processing, computational medicine, and machine learning
BRYCE BENSON, PHD
DATA SCIENTIST
Expert in bioengineering, cardiac electrophysiology, signal processing, biomedical data analysis
ADAM HILLIG, RN, BSN, CFRN
CLINICAL SPECIALIST
Registered Nurse with 20+ years of critical care and flight nursing experience. Trusted execution partner with deep appreciation of the clinician experience.
TOM SHEHAB, MD
BOARD MEMBER
Over 25 years of diverse healthcare experience as a physician, healthcare executive, and successful venture capitalist
BILL SCHMIDT
BOARD MEMBER
25+ years experience in medical device and health IT sectors, including successfully building and exiting a digital health company and serving as Managing Director of Cultivation Capital’s Life Sciences Fund.
AELIN
CHIEF CANINE OFFICER
Friend to all. Lover of a power nap.
Our Partners
